Formulary Status
Nationwide, over 80% of patients with prescription drug coverage pay a Tier 1 or Tier 2 copay.1||
Use the free formulary status tool to quickly determine the formulary status of asthma controllers, including SYMBICORT, in your area.
Asthma Patient Support
Encourage your patients to sign up for appointment and refill reminders, air quality and pollen count alerts, and savings on prescription copays.
In fixed-combination maintenance treatment of asthma
SYMBICORT helps patients breathe better by providing sustained control* with rapid improvement in lung function at each dose2,3,†
- SYMBICORT helped patients breathe better within 15 minutes2 and this control was sustained over the long-term3,*
- Each dose† of SYMBICORT provided rapid improvement in lung function within 15 minutes2,3,*
- Most patients felt SYMBICORT begin to work right away4-6,‡
— a general preference in a maintenance medication7, §
Patients who experienced rapid improvement in lung function were not necessarily the same patients who reported feeling SYMBICORT begin to work right away.
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms.
Select a module below to view key information about SYMBICORT
efficacy, safety, dosing, and patient profiles.
Efficacy Data
Review measures of asthma control as demonstrated in clinical studies.
Dosing Information
Learn about dosing SYMBICORT.
Safety Information
Learn about the most common side effects associated with SYMBICORT.
Patient Profiles
Review which types of patients can benefit from SYMBICORT therapy.
* Onset of clinically significant bronchodilation (>15% improvement in forced expiratory volume in 1 second [FEV1]) occurred within 15 minutes (median time). In pivotal US clinical studies, asthma control was defined as the coprimary efficacy end points of the 12-hour-average postdose FEV1 at week 2 and predose FEV1, averaged over 12 weeks.
† Mean percent change from baseline FEV1 was measured at day of randomization, week 2, and end of treatment.
‡ Sixty-nine percent of patients reported feeling SYMBICORT begin to work right away during the first week of treatment. Throughout the study, most patients reported feeling it begin to work right away. These data are based on results from a subset of patients >18 years of age (n=442) participating in a 12-week efficacy and safety study for SYMBICORT. Patients were assessed on a weekly basis using the Onset of Effect Questionnaire, administered through an electronic diary to record their responses to 5 statements concerning onset of medication.
§ In a study that offered a choice of hypothetical product profiles to patients treated with combination inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) therapy, a majority of patients responded that they would choose a maintenance medication that they felt "begin to work right away."
|| Individual costs may vary by plan.